Literature DB >> 27904744

QT interval prolongation and torsades de pointes with oxaliplatin.

Jules C Hancox1, Rachel E Caves1, Stéphanie C M Choisy1, Andrew F James1.   

Abstract

Entities:  

Year:  2016        PMID： 27904744      PMCID： PMC5117153          DOI： 10.1177/2042098616666081

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  13 in total

Review 1.  Oxaliplatin: a review of approved uses.

Authors:  Alexander Stein; Dirk Arnold
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

2.  Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer.

Authors:  Hyun-Joong Kim; Sang Hee An; Yo Han Cho; Sung-Yong Kim; Hong Ghi Lee; So Young Yoon
Journal:  Acta Oncol       Date:  2013-02-01       Impact factor: 4.089

Review 3.  Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.

Authors:  Francesco Montagnani; Gina Turrisi; Claudio Marinozzi; Camillo Aliberti; Giammaria Fiorentini
Journal:  Gastric Cancer       Date:  2011-02-23       Impact factor: 7.370

Review 4.  Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.

Authors:  Peter J Schwartz; Raymond L Woosley
Journal:  J Am Coll Cardiol       Date:  2016-04-05       Impact factor: 24.094

5.  Human ether-à-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer.

Authors:  Riping Zhang; Pei Tian; Qiang Chi; Jizhou Wang; Yongwei Wang; Lingyu Sun; Yang Liu; Suli Tian; Qifan Zhang
Journal:  Oncol Rep       Date:  2011-10-21       Impact factor: 3.906

6.  Oxaliplatin: a review in the era of molecularly targeted therapy.

Authors:  T Alcindor; N Beauger
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

7.  Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current.

Authors:  Ruth Sittl; Angelika Lampert; Tobias Huth; E Theresa Schuy; Andrea S Link; Johannes Fleckenstein; Christian Alzheimer; Peter Grafe; Richard W Carr
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

8.  The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells.

Authors:  Sheng-Nan Wu; Bing-Shuo Chen; Yung-Han Wu; Hsung Peng; Li-Tzong Chen
Journal:  Neurotoxicology       Date:  2009-05-05       Impact factor: 4.294

Review 9.  The hERG potassium channel and hERG screening for drug-induced torsades de pointes.

Authors:  Jules C Hancox; Mark J McPate; Aziza El Harchi; Yi Hong Zhang
Journal:  Pharmacol Ther       Date:  2008-06-18       Impact factor: 12.310

10.  The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat.

Authors:  Alexia Kagiava; Anastasia Tsingotjidou; Christos Emmanouilides; George Theophilidis
Journal:  Neurotoxicology       Date:  2008-09-18       Impact factor: 4.294
View more
  1 in total

Review 1.  Emerging Challenges to the Safe and Effective Use of Methadone for Cancer-Related Pain in Paediatric and Adult Patient Populations.

Authors:  Kyle P Edmonds; Ila M Saunders; Andrew Willeford; Toluwalase A Ajayi; Rabia S Atayee
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.